Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05526391 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-341 in Treatment of Multiple System Atrophy
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT05526391 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 158 participants.
The verdict
NCT05526391, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.
Interventions
- DRUG Placebo
- DRUG TAK-341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2025-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05526391
The ClinicalTrials.gov registry entry for NCT05526391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05526391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05526391 about?
NCT05526391 is a clinical study titled "A Study of TAK-341 in Treatment of Multiple System Atrophy". The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every...
What is the current status of trial NCT05526391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2022-11-16. Estimated completion is 2025-07-28.
What interventions are being tested in trial NCT05526391?
The interventions under investigation include: Placebo (DRUG), TAK-341 (DRUG).
Who is sponsoring clinical trial NCT05526391?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.